Prostate Cancer

Radium 223 dichloride (Ra 223 [Xofigo]) can be safely combined with abiraterone acetate (ZYTIGA) for the treatment of patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, and appears to result in decreased bone pain and improved quality of life, according to the interim results of an open-label prospective study known as eRADicAte.

Urology Times SUO internship program member Cory Hugen, MD, reports on a recent Mayo Clinic study on familial history’s impact on post-RP outcomes and survival.

A leader in urologic oncology discusses four currently available molecular tests in this report from Urology Times SUO internship program member Brandon Manley, MD.

In a recently published study, researchers analyzed data from nearly 20,000 high-risk prostate cancer patients at more than 1,000 facilities.

Findings from a recent study emphasize the need for imaging with CT or MRI and bone scan to determine the pattern of spread in men with advanced prostate cancer.

Check out the latest products. From an MRI System that improves lesion conspicuity, a biopsy device receives FDA clearance and an App that tracks stent implants.

Surveillance “should be more commonly used for patients with low-risk prostate cancer,” argues an author of the endorsement.

Physicians at Vanderbilt University Medical Center, Nashville, have opened a dedicated cardio-oncology service, including urology, medical oncology, radiation oncology, and cardiology.

"What we need most are markers that selectively identify significant cancers, in order to reduce unnecessary biopsies and over-diagnosis," writes Stacy Loeb, MD, MSc.

Two urinary biomarkers for detection of prostate cancer have differing utility in African-American men undergoing prostate biopsy.

New findings from the Johns Hopkins University School of Medicine in Baltimore should be useful to clinicians looking to counsel anxious prostate cancer patients who are undergoing active surveillance.

Four PCa studies presented at the 2015 AUA annual meeting in New Orleans shed some light, with researchers emphasizing the need to optimize screening and to improve treatment selection in older men.

“Both physicians and patients should take into account remaining life expectancy before adopting screening pathways,” a study author says.

The investigational modality was compared with surgical pathology in men undergoing radical prostatectomy.

Urology Times SUO internship program member Brandon Manley, MD, reports on an SUO presentation highlighting several interesting findings on advanced prostate cancer with variant histology.

Researchers hypothesized that during a time of resource scarcity, the incidence of PSA-detected prostate cancer would decrease and the use of noncurative management strategies would increase, reports Urology Times SUO internship program member Ryan Hutchinson, MD.

Analyses of overall survival rates among subgroups of men who received radium-223 dichloride (Ra 223; Xofigo) as part of an expanded access program suggest factors that may have prognostic significance, including effects of prior and concomitant treatments.

Check out the latest new products. From Single-use ureteroscope addresses shortcomings of reusable scopes, to an App that helps IC, chronic prostatitis patients choose the right foods and much more.

Results of a recently published study examining the safety of the two approaches support stronger consideration for orchiectomy, according to its authors.

Findings of a large study examining histology of newly diagnosed prostate cancer point to concerning trends in the aftermath of the USPSTF’s recommendation against PSA-based screening.

Number of preoperative biopsies does not appear to have any clinically significant effect on self-reported urinary or erectile function outcomes at 1 year after radical prostatectomy, researchers say.

A combination of findings on preoperative multi-parametric magnetic resonance imaging showed good accuracy for predicting lymph node involvement on final pathology in men who underwent robot-assisted radical prostatectomy for prostate cancer, reported researchers from the National Institutes of Health, Bethesda, MD.

"We’re definitely seeing fewer men referred for elevated PSAs," one urologist told Urology Times.

Other pipeline products discussed in this article include an immunotherapy for metastatic bladder cancer, a treatment for lower urinary tract symptoms of BPH, and an investigational clear cell renal cell carcinoma treatment.

Evaluation of online videos is a feasible method for peer review of robot-assisted radical prostatectomy surgical skills, according to a pilot project undertaken by the Michigan Urological Surgery Improvement Collaborative (MUSIC).